Oval Medical Technologies, which develops patient-centric autoinjectors, has signalled a new stage in its growth with a move to a purpose-designed facility in Cambridge Research Park.
Andrew Wilkinson
The new facility provides good manufacturing practice (GMP) labs, enhanced device development, space to house the expanded team, and room for growth supporting pharmaceutical companies’ needs for injection platforms to deliver subcutaneous and intramuscular drug formulations.
Barbara Lead, chief executive officer of Oval Medical Technologies, said: “Our autoinjector platforms are creating huge opportunities for pharmaceutical companies to develop new products and to improve established formulations. This move provides the needed space to continue to grow and develop cutting edge technology platforms serving pharmaceutical companies and patients.”
Established in 2009, Oval has experienced continued growth since its December 2016 acquisition by global medical device contract manufacturer SMC. The integrated business provides a ‘one stop shop’, from device design to delivery of finished commercial product.
Demand for Oval’s advanced technology is being driven by the growth in biologic and long acting formulation injections. Oval’s patient-centric autoinjector platforms are matched to the specific needs of target patient populations. Designed around Oval’s integrated Primary Drug Containers (PDCs), the company’s autoinjectors are small devices providing consistent delivery performance.
Oval’s chief technology officer, Matthew Young, added: “Our principal aim is to partner our patient-centric autoinjectors with an integrated start to finish solution – one that’s easy for patients and easy for partners. Our expanded new facility makes that objective more achievable.”
